ClariVein® mechanochemical endovenous ablation: patient selection and perspective

Amjad Belramman1
Roshan Bootun1,2
Sarah Onida1,3
Alun H Davies1,3
Tristan RA Lane1,3

1Academic Section of Vascular Surgery, Department of Surgery and Cancer, Imperial College London, London, UK; 2East of England Deanery Vascular Surgery Training Programme, Cambridge, UK; 3Imperial Vascular Unit, Imperial College Healthcare NHS Trust, London, UK

Abstract: The American Venous Forum and the National Institute for Health and Care Excellence recommend endothermal ablation (ETA) techniques as the first line treatment for superficial venous incompetence. However, these techniques require the use of tumescent anaesthesia prior to energy delivery, which may be a source of discomfort for the patient and can prolong procedure time. Recently, nonthermal, nontumescent (NTNTs) techniques such as mechanochemical ablation (MOCA) have been developed to address some of the negative aspects associated with ETA. This article reviews this technique from a patient selection and perspective point view.

Keywords: endovenous ablation, varicose veins, venous disease, mechanochemical ablation

Introduction

Varicose veins are a common condition affecting up to one-third of the population, with detrimental effects on quality of life (QoL).1,2 Forty thousand vein interventions are performed each year on the National Health Service (NHS) alone. Until the turn of the millennium, the traditional technique of ligation of the saphenofemoral (SFJ) or saphenopopliteal junction (SPJ) with or without vein stripping was the gold standard treatment for great and small saphenous incompetence. However, this has largely been replaced by endovenous (within the vein) thermal ablation (ETA) techniques. These endovenous techniques have dramatically changed the treatment of truncal venous reflux and are routinely performed as office-based local anaesthetic procedures. This has led to a reduction in morbidity3-5 compared to open surgery by reducing postoperative pain, providing faster recovery, improving QoL, and lowering complication rates.6,7 Long term trial follow-up has suggested that recurrence rates are lower in ETA compared to surgery.8 Therefore, both the American Venous Forum and the National Institute for Health and Care Excellence (NICE) have recommended ETA as the first line treatment for superficial venous incompetence since 20119 and 2013,10 respectively. However, these techniques require the use of tumescent anaesthesia prior to energy delivery, which can be a source of discomfort for the patient and prolongs procedure time.11 More recently, nonthermal, nontumescent (NTNTs) techniques have been developed to minimise these negative aspects associated with ETA. Mechanochemical ablation (MOCA) is one such method, with the brand name of ClariVein® (Merit Medical, Utah, USA) (Figure 1). It was developed in 2005 by Michael Tal and his colleagues and obtained a CE mark in 2010.12 In 2016, NICE issued interventional procedural guidance permitting the use of the MOCA for the treatment of varicose vein in the United Kingdom as a standard treatment.10
The principle of this method has been reported before and combines mechanical abrasion of the venous wall using a rotating wire (3500 rpm) with simultaneous injection of liquid sclerosant (Figure 2). Since no heat is applied, the use of tumescent anaesthesia is not needed.

The technique utilizes the standard endovenous ablation approach - modified Seldinger ultrasound guided vein puncture for cannulation, which can be with a micropuncture kit, use of an access sheath and then the MOCA catheter is passed up the vein using ultrasound guidance to ensure accurate placement of the catheter tip 2cm from the SFJ (Figures 3 and 4). The tip of the device is then unsheathed (and accurate placement confirmed) before treatment is commenced. This requires activation of the rotation motor with pullback of the catheter (at a rate of 7 seconds per cm) and instillation of sclerosant by hand using an attached syringe (Figure 5). To the patient it feels like a “buzzing”/“electric toothbrush” sensation.

The push-pull (push syringe and pull catheter) whilst pressing the motor button does have a learning curve but after this is reproducible and reliable.

Recently, two animal and ex vivo studies have shown that both the mechanical and chemical components are necessary to obtain optimum treatment results.

![Figure 1](image1.png)

**Figure 1** The ClariVein® mechanochemical ablation catheter.

**Note:** Photo courtesy of Merit Medical.

![Figure 2](image2.png)

**Figure 2** (A) Device inside the vein. (B) Mechanism action of action (Wire rotating and sclerosant injection).

![Figure 3](image3.png)

**Figure 3** Introduction of the catheter via sheath.

![Figure 4](image4.png)

**Figure 4** Ultrasound images showing tip of MOCA catheter.
Patient selection

General considerations

The device is designed to treat refluxing truncal veins as with other endovenous ablation devices. When treating patients with the MOCA device, it is vital to assess the length of vein appropriately. As the device is 2 2/3Fr in calibre and is compatible with an 18-gauge cannula (3.8Fr), it is tempting to puncture as distally as possible. However, whilst the device is available in 45/65/85 cm lengths, the working length is 5 cm shorter due to the taper at the handle. A 4Fr vessel is only 1.33 mm in diameter and therefore may be difficult to puncture appropriately.

Dosage and concentration of sclerosant utilised during the treatment have limited evidence. A dose finding study currently being undertaken has shown that 2% and 3% polidocanol liquid sclerosant have equivalent efficacy but that 1% polidocanol foam is inferior when used with MOCA. Most studies utilise either 1.5% or 2% sodium tetradecyl sulphate (STS) sclerosant or polidocanol (POL). Robust evidence on optimum concentration is lacking. The instructions for use (IFU) provide a nomogram for dosing which suggests a maximum dosage of 10 mL of sclerosant. There is no evidence on toxicity in the MOCA context and this dosage is extrapolated from sclerotherapy guidelines.

The procedure is reportedly less painful than radio-frequency ablation and, so, is often better tolerated than tumescent injections. However, the patient should always be warned of the unusual nature of the sensation produced by the device (the authors liken it to an electric toothbrush) as when the first segment is treated without warning, patients may flinch or move, displacing the catheter tip. Similarly, a complete lack of feedback indicates incorrect positioning and need for review.

For assessment of the treated segment patience is key, as the chemical process invoked takes time. Rapid assessment may lead to overtreatment of the proximal segment and subsequent under-treatment of distal segments due to sclerosant volume limitations.

Recurrent or phlebitic veins

Initial experience with MOCA suggested that patients with fibrotic or previously treated truncal veins were not suitable for treatment with this technique. This is due to the fact that the webs and synechiae that arise inside the vein can catch the rotating tip of the device. However, with increasing experience, it is evident that this seldom leads to significant pain or problems. If the rotating tip catches in a web, or a sclerotic valve, usually identified by a slowing of the motor and increased motor noise, this can be managed by stopping the motor then unwinding slightly in an anticlockwise direction, which frees the tip in most cases. Alternatively, a small tug (with or without a local anaesthetic injection) will release the device. In the worst cases, a small incision and dissection to the vein will allow direct surgical release. If the catheter tip does catch in the vein this should not be treated as a failure – the intimal damage...
causing the catching will allow ingress of sclerosant and appropriate treatment.

**Superficial or small veins**

Superficial and small veins need consideration as the vibration sensation can be extremely intense and can be painful. These types of veins benefit from a slower motor speed to allow comfortable treatment.

Superficial veins treated with MOCA appear to have an excellent result with a reduced risk of skin pigmentation or burn compared to endothermal techniques.

**Anticoagulation**

Anticoagulation is not a barrier to treatment, similar to other endovenous techniques. It does, however, reduce the risk of postoperative thrombosis. There is no evidence to suggest that MOCA has a different efficacy in anticoagulated patients.

**Active ulceration and advanced disease**

MOCA offers the opportunity of treating below the ulcer via a retrograde approach. Due to the nature of treatment, without thermal energy but with sclerosant dispersal, the sub-ulcer plexus is treated without the risk of nerve injury.

MOCA also allows treatment without tumescent injections so veins under fragile skin can be treated safely – potentially with the use of antegrade and retrograde access.

**Tortuous truncal veins**

Tortuous truncal veins have always been a significant hurdle; however, the steerable nature of the angled catheter tip allows traversal of most truncal veins.

**Large veins**

Many surgeons initially feared that endovenous thermal ablation would not be able to treat large veins effectively. However, extensive experience has shown that this apprehension is misplaced. The same appears to apply to MOCA. The catheter tip rotation diameter will easily treat diameters of 20–24 mm, especially when treated in the Trendelenburg position. Patients should be able to feel the device working – a lack of feedback indicates a need for treatment adjustment. Due to the nature of MOCA, partial ablation leads to a narrowed vein, which may be sufficient for symptomatic improvement, and as is seen in other modalities, technical success does not always indicate clinical success.

**Clinical data**

**Prospective studies**

In 2012, Elias et al published the first-in-man clinical trial on the safety and efficacy of using the ClariVein device to treat the great saphenous vein (GSV). Twenty-nine patients (30 GSVs) were recruited with an average age of 54 years. The majority of patients were Clinical-Etiological-Anatomical-Pathophysiological (CEAP) Class 2 and the average diameter of the treated vein was 8.1 mm (5.5–13 mm). 1.5% liquid STS was used as a sclerosant solution. During the procedures, all patients were free of pain and no analgesia was required. At 6 months follow-up, there was a 97.6% occlusion rate. Twenty-four patients attended 2-year follow-up and all treated veins were successfully occluded. No major adverse complications, including deep vein thromboses (DVTs), skin or nerve injury, were reported. However, it is to be noted that 77% of patients did not have advanced disease. Three patients had ecchymosis and the authors presumed that this was due to the rotating wire getting caught on the vein wall or valve cusp. The authors deemed MOCA to be safe and efficacious in the treatment of saphenous vein reflux.

A second clinical study was conducted in the Netherlands to assess the clinical efficacy of this device with 30 GSVs in 25 patients using POL (Aethoxysklerol, Kreussler Pharma, Wiesbaden, Germany) at two hospitals. The initial technical success rate was 100% but 26 of 30 GSV (87%) remained closed at 6 weeks. Three veins showed partial recanalization, one vein developed complete recanalization and nine patients had localised ecchymosis at the puncture site. There was also transient superficial phlebitis in 4 limbs. No other major adverse event was noted. Median peri-procedural maximal pain score was 4 (IQR 3–6) and the mean maximum pain on the first postoperative day was 9 (0–100 mm visual analogue scale [VAS]); patient satisfaction was high (median 8.5 [IQR 8–9] on a 10-point scale). Compared to baseline, the median venous clinical severity score (VCSS) improved significantly from 3.0 to 1.0 ($p<0.001$) 6 weeks after treatment. This study, therefore, demonstrated that MOCA, using POL, was again safe and feasible in the treatment of venous reflux. However, this study only included patients with GSV incompetence.
In order to investigate the effectiveness of the MOCA on small saphenous vein insufficiency, Boersma et al.\textsuperscript{22} conducted a prospective, non-controlled, observational study in which 55 SSV reflux patients were treated using ClariVein with POL and followed up for 12 months, which was the longest follow-up in the literature at that time. Occlusion rates at 6 months and 1-year follow-up were 100% and 94%, respectively, and no major complications, including nerve injury, were noted. The median VAS peri-procedural pain score was 20 mm (IQR 20–40 mm) and the median patient satisfaction was 8 (IQR 8–9) at 6 weeks. Clinical disease severity, measured via VCSS, was significantly decreased from 3 at baseline to 1 (IQR 1–3, \( p < 0.001 \)) at 6 weeks. At 1-year follow up, VCSS scores were also 1 (IQR 1–2, \( p < 0.001 \)).

In the following year, van Eekeren\textsuperscript{23} and his colleagues evaluated 92 patients (106 limbs) undergoing MOCA for GSV insufficiency. Sixty-seven of the patients were females with a mean age of 52 years. Two concentration of POL (1.5% to 10 proximal segments and 2% for the remaining segment) were used. The median post-procedural pain score during the first 14 days after treatment was 7.5 mm (IQR 0.0–10.0 mm) on a 100 mm visual analogue scale. The median time to return to normal activities was noted as 1.0 day (IQR, 0.0–1.0 day), and the time to return to work for employees was 1.0 day (IQR, 1.0–4.0 days). Superficial thrombophlebitis (3%), induration (12%), localized haematoma (9%), and mild hyperpigmentation at the puncture site (5%) were observed. However, no major adverse events such as DVT, saphenous nerve neuralgia, and skin necrosis were noted. Technical success (defined as performing the procedure without technical problem) was achieved in 99% (105/106). A total of 93.2% of the treated veins remained obliterated at six months. Eight patients developed recanalization (4 complete, 8 partial) giving a primary closure rate of 88.2% at 1-year follow-up. Both clinical disease severity and disease-specific QoL improved significantly at the 6-month and 12-month follow-up (\( p < 0.001 \)). At 3-year follow-up, the clinical success and anatomical success were 83.1% and 86.5%, respectively. Although patient-reported health status remained significantly improved up to 36 months follow up, a significant deterioration in the venous clinical severity score (VCSS) was observed. The authors attributed this to the recurrent nature of varicose veins.\textsuperscript{24}

**Tumescent-based versus tumescent-less**

Data from a non-randomised study of MOCA compared to radiofrequency ablation (RFA) in sixty-eight patients with GSV incompetence demonstrated significantly less postoperative pain, faster recovery, and earlier work resumption in the MOCA group. At 6 weeks, both groups had a significant improvement in health status and disease-specific QoL. Limitations of the study include its non-randomized design, the absence of criteria used for patient selection and non-inclusion of the occlusion rate. Finally, the procedural pain was not significantly different between the two groups and the authors suggested that this was because of the small sample size in the study.\textsuperscript{17}

Lower pain scores with MOCA were confirmed in a randomised controlled trial (RCT) of MOCA (Clarivein) versus RFA (Venefit). One hundred and seventy patients with primary truncal venous incompetence were recruited and randomised to receive either MOCA or RFA. The primary study end point was pain level during the procedure. This was evaluated by a VAS, which demonstrated that MOCA was significantly less painful (median 15 mm [IQR: 7–36 mm]) than RFA (median 34 mm [IQR: 16–53]) \( (p = 0.003) \). Patients undergoing MOCA also reported less pain on a 0 to 10 number scale (median 3 [IQR: 1–5]) than RFA (4 [IQR: 3–6.5]; \( p = 0.002 \)). Both the MOCA and RFA groups had similar improvement in clinical severity scores, disease-specific or generic QoL scores, and time to resume normal activities. Occlusion rates were also comparable. One case of DVT was reported in each group.\textsuperscript{11,18}

**Tumescent-less versus tumescent-less**

Interrogation of four international registries reveals only one trial aiming to compare an endovenous tumescentless method with another. This study, the MOCCA randomised controlled trial\textsuperscript{25} (mechanochemical ablation versus cyanoacrylate adhesive in the treatment of truncal saphenous incompetence) was designed to compare the degree of pain that patients experience while receiving MOCA or CAE ablation. So far, the trial has recruited 120 patients of the target 180, and the final results of this trial are expected towards the end of 2020.

The published studies about MOCA of superficial veins are summarized in Tables 1 and 2.

**Complication profile**

Complications after endovenous ablation are rare, and MOCA offers a different profile. Nerve injury is extremely rare due to the non-thermal nature, and very few venous thromboembolism events have been recorded in the literature. Phlebitis has been reported in equal rates to endothermal ablation. Recurrence appears to be similar to other...
Table 1: Published prospective studies of mechanochemical ablation for saphenous reflux

<table>
<thead>
<tr>
<th>Study author, Year</th>
<th>Vein</th>
<th>CEAP</th>
<th>Sample size (No. of limbs)</th>
<th>Diameter (mm)</th>
<th>Type of Sclerosant</th>
<th>Technical success</th>
<th>Anatomical success</th>
<th>Recanalize</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elias et al, 2012</td>
<td>GSV</td>
<td>C2-4a</td>
<td>30</td>
<td>8.1 mm (5.5–13)</td>
<td>STS 1.5%</td>
<td>100</td>
<td>96 (6 months)</td>
<td>1 vein</td>
<td>6 months</td>
</tr>
<tr>
<td>van Eekeren et al, 2011</td>
<td>GSV</td>
<td>C2-4</td>
<td>30</td>
<td>6.1 mm</td>
<td>POL 1.5%</td>
<td>100</td>
<td>87</td>
<td>N/A</td>
<td>6 weeks</td>
</tr>
<tr>
<td>Boersma et al, 2012</td>
<td>SSV</td>
<td>C2-6</td>
<td>50</td>
<td>4.8 (3.5–7)</td>
<td>POL (1.5 &amp; 2%)</td>
<td>100</td>
<td>94 (44 out of 47)</td>
<td>3 veins</td>
<td>12 months</td>
</tr>
<tr>
<td>van Eekeren et al, 2014</td>
<td>C2-5</td>
<td>105</td>
<td>5.5 (5.0–7.0)</td>
<td>POL (1.5&amp;2%)</td>
<td>99</td>
<td>88 (90 out of 102)</td>
<td>12 veins</td>
<td>12 months</td>
<td></td>
</tr>
<tr>
<td>Bishawi et al, 2014</td>
<td>GSV</td>
<td>C1-6</td>
<td>126</td>
<td>7.3±2.6</td>
<td>STS 1.5% and POL 1.5%</td>
<td>100</td>
<td>94 (120 out 126)</td>
<td>6 veins</td>
<td>6 months</td>
</tr>
<tr>
<td>Deijen et al, 2016</td>
<td>GSV/SSV</td>
<td>C2-6</td>
<td>506</td>
<td>N/A</td>
<td>POL (1.5&amp;2%)</td>
<td>100</td>
<td>90% (92 for GSV 84% for SSV)</td>
<td>49 veins</td>
<td>12 weeks</td>
</tr>
<tr>
<td>Kim et al, 2017</td>
<td>GSV</td>
<td>C2-4</td>
<td>126</td>
<td>7.6</td>
<td>STS 1.5% (84) and POL 1.5% (16)</td>
<td>100</td>
<td>92% (65 out 126)</td>
<td>5 veins</td>
<td>24 months</td>
</tr>
<tr>
<td>Tang et al, 2017</td>
<td>GSV/SSV</td>
<td>C2-C6</td>
<td>371</td>
<td>GSV 6.4 SSV 5</td>
<td>STS 2%</td>
<td>100</td>
<td>GSV 97 SSV 100</td>
<td>1 vein</td>
<td>8 weeks</td>
</tr>
</tbody>
</table>

Abbreviations: CEAP, Clinical-Etiological-Anatomical-Pathophysiological; GSV, great saphenous vein; SSV, Small saphenous vein; STS, sodium tetradecyl sulphate; POL, polidocanol; N/A, not available.

Table 2: Published comparative studies of MOCA of superficial veins

<table>
<thead>
<tr>
<th>Study author, Year</th>
<th>Vein</th>
<th>CEAP</th>
<th>Sample size (No. of limbs)</th>
<th>Diameter (mm)</th>
<th>Type of Sclerosant</th>
<th>Technical success</th>
<th>Anatomical success</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>van Eekeren et al, 2013</td>
<td>GSV</td>
<td>C1-6</td>
<td>68</td>
<td>RFA 5.7 MOCA 6.8</td>
<td>POL (1.5 and 2%)</td>
<td>N/A</td>
<td>N/A</td>
<td>6 weeks</td>
</tr>
<tr>
<td>Lane et al, 2016</td>
<td>GSV/SSV</td>
<td>C2-6</td>
<td>170</td>
<td>7</td>
<td>STS 2%</td>
<td>N/A</td>
<td>93% for RFA 87% for MOCA</td>
<td>6 months</td>
</tr>
<tr>
<td>Leung et al, 2017</td>
<td>GSV/SSV</td>
<td>N/A</td>
<td>82</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>94% for EVLA 92% for MOCA</td>
<td>6 months</td>
</tr>
<tr>
<td>Khor et al, 2018</td>
<td>GSV/SSV</td>
<td>C2-S</td>
<td>180</td>
<td>GSV 5.6±1.0 mm SSV 4.2±1.2 mm</td>
<td>STS 2.0%</td>
<td>100%</td>
<td>84.8% for GSV 94.3% for SSV</td>
<td>12 months</td>
</tr>
</tbody>
</table>

Abbreviations: CAE, cyanoacrylate embolisation; CEAP, Clinical-Etiological-Anatomical-Pathophysiological; EVLA, endovenous laser ablation; GSV, great saphenous vein; MOCA, mechanochemical ablation; RFA, radiofrequency ablation; STS, sodium tetradecyl sulphate; POL, polidocanol; SSV, small saphenous vein; N/A, not available.
Advantages and disadvantages

MOCA has its own unique advantages and disadvantages in the management of superficial venous incompetence as shown in Table 3 below.

Disclosure

Mr Roshan Bootun reports grants from Graham-Dixon Charitable Trust and Kreussler, outside the submitted work. The authors report no other conflicts of interest in this work.

References


Table 3 MOCA advantages and disadvantages

<table>
<thead>
<tr>
<th>Advantage</th>
<th>Disadvantage</th>
</tr>
</thead>
<tbody>
<tr>
<td>• No need for an energy generator.</td>
<td>• Vein diameter if &gt;20–24 mm</td>
</tr>
<tr>
<td>• Handheld (portable)</td>
<td>• Dose limitation of sclerosant</td>
</tr>
<tr>
<td>• Non-heated base, so no tumescence is required (reduce procedural time)</td>
<td>• May be difficult in partially occluded or fibrotic</td>
</tr>
<tr>
<td>• No risk of nerve injury when treating any below-knee segment of vein</td>
<td>• Compression stocking required</td>
</tr>
<tr>
<td>• Multiple, bilateral truncal vein to be ablated at the same session</td>
<td>• Pullback and inject sclerosant simultaneously</td>
</tr>
<tr>
<td>• Safe in a very superficial vein</td>
<td>• A learning curve for optimal results</td>
</tr>
<tr>
<td>• Access can be made retrograde in advanced venous disease</td>
<td>• Potential risk from sclerosant</td>
</tr>
<tr>
<td>• Steerable catheter so able to traverse tortuous veins</td>
<td>• Single use</td>
</tr>
<tr>
<td>• Available in different lengths</td>
<td></td>
</tr>
</tbody>
</table>

endovenous techniques. Despite the use of sclerosant, there have been no reports of neurological events.

Acknowledgements

The research was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London. The views expressed are those of the authors and not necessarily those of the NHS, NIHR or the Department of Health. SO is supported by an NIHR Clinical Lectureship and acknowledges support from the NIHR Imperial Biomedical Research Centre.


